Guangdong Taienkang Pharmaceutical (301263.SZ) subsidiary obtains preliminary analysis results from Phase IIa clinical trial for CKBA cream rosacea indication.

Guangdong Taienkang Pharmaceutical (301263.SZ) announced that recently, the Phase IIa clinical trial for the rosacea indication of CKBA cream, a Class 1 innovative drug independently developed by the company's controlling subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., has recently completed data collation. Preliminary analysis results show that 1.50% CKBA cream has good efficacy and safety in treating moderate to severe papulopustular rosacea. After 16 weeks of treatment, the proportion of subjects whose Investigator's Global Assessment (IGA) score reached 0 or 1 was 60.00% (9/15), and the inflammatory lesion count (ILC) decreased by 39.06 from baseline, a reduction of 76.40%. It is reported that this Phase IIa clinical trial, despite the relatively high baseline ILC and IGA of enrolled subjects, including the severe patient subgroup, demonstrated good short-term efficacy, long-term therapeutic potential, and excellent safety, providing a strong basis for the smooth advancement of subsequent Phase IIb/III clinical trials. Based on the positive and effective preliminary data from Phase IIa, the company has already initiated the Phase IIb clinical trial ahead of schedule and completed the enrollment of the first subject in early September 2026. The company will further accelerate the Phase IIb/III clinical trials.